缺血性卒中或短暂性脑缺血发作患者抗血小板药治疗期间血小板高反应性  

High on-treatment platelet reactivity in patients with ischemic stroke or transient ischemic attack

作　　者：张丽萍 孙增先 Zhang Liping;Sun Zengxian(The Affiliated Lianyungang Hospital of Xuzhou Medical University,Lianyungang 222006,China;Department of Pharmacy,the Affiliated Lianyungang Hospital of Xuzhou Medical University(The First People's Hospital of Lianyungang),Lianyungang 222006,China)

机构地区：[1]徐州医科大学附属连云港医院,连云港222006 [2]徐州医科大学附属连云港医院(连云港市第一人民医院)药学部,连云港222006

出　　处：《国际脑血管病杂志》2023年第12期918-924,共7页International Journal of Cerebrovascular Diseases

摘　　要：抗血小板药是指南推荐的缺血性卒中/短暂性脑缺血发作(transient ischemic attack,TIA)长期治疗及二级预防的基石,用于降低复发性卒中及其他心血管事件风险。然而,某些缺血性卒中/TIA患者在抗血小板治疗期间仍会出现缺血性事件,称为治疗期间血小板高反应性(high on-treatment platelet reactivity,HTPR),通常发生在服用阿司匹林或氯吡格雷的患者中。文章阐述了缺血性卒中/TIA患者中HTPR的发生率、危险因素和常用评价方法,阐述HTPR在缺血性卒中/TIA患者中的临床意义,并探讨HTPR患者的抗血小板治疗方案。Antiplatelet drugs are the cornerstone of long-term treatment and secondary prevention for ischemic stroke/transient ischemic attack(TIA)recommended by guidelines,aimed at reducing the risk of recurrent stroke and other cardiovascular events.However,some patients with ischemic stroke/TIA may still experience ischemic events during antiplatelet therapy,known as high on-treatment platelet reactivity(HTPR),which typically occurs in patients taking aspirin or clopidogrel.This article elaborates the incidence,risk factors,and commonly used evaluation methods of HTPR in patients with ischemic stroke/TIA,and elucidates the clinical significance of HTPR in patients with ischemic stroke/TIA,and investigates the antiplatelet treatment protocol of patients with HTPR.

关 键 词：缺血性卒中 脑缺血发作 短暂性 抗血小板聚集药 阿司匹林 氯吡格雷 双联抗血小板治疗 血小板聚集 血小板功能试验 

分 类 号：R743.3[医药卫生—神经病学与精神病学]